Efficacy and Limitations of 68-Gallium DOTATATE PET/CT for Neuroendocrine Tumors: Clinical Experience Following FDA Approval

HPB - United Kingdom
doi 10.1016/j.hpb.2018.02.344
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Comparison of 68Ga-Dotatate and 18f-FDG PET/CT in Pulmonary Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2009English

Neuroendocrine Tumor Recurrence: Diagnosis With68Ga-Dotatate PET/CT

Radiology
Nuclear MedicineRadiologyImaging
2013English

68Ga-Dotatate PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients With Well-Differentiated Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2010English

Clinical and Morphological Characteristics of Neuroendocrine Tumors: Clinical Experience

Advances in molecular oncology
2017English

Uterine Tumors and PET-CT

Bangladesh Journal of Nuclear Medicine
2018English

Localization of Unknown Primary Site With 68 Ga-Dotatoc PET/CT in Patients With Metastatic Neuroendocrine Tumor

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

18f-FDG PET/CT Can Be Used to Detect Non-Functioning Pancreatic Neuroendocrine Tumors

International Journal of Oncology
Cancer ResearchOncology
2014English

PET/CT and Occult Primary Tumors

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2009English

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy